NYU Langone experts will join colleagues from around the globe at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.

Below are notable sessions featuring our faculty and trainees. For a full list of presentations, visit the ASCO website.

Saturday, May 31

Poster
Abstract 3608: Time-weighted ctDNA dynamics for precision monitoring of relapse risk in colon cancer
Session: Gastrointestinal Cancer— Colorectal and Anal
Presenter: Alessandro Leal, MD, PhD
Time: 9:00 AM–12:00 PM
Location: Hall A, Poster Board #277

Poster
Abstract 2072: Development and validation of a droplet digital PCR (ddPCR) assay to detect MGMT promoter methylation in FFPE tumors of glioblastoma (GBM) patients
Session: Central Nervous System Tumors
Presenter: Mahrukh M. Syeda, MS
Time: 9:00 AM–12:00 PM
Location: Hall A, Poster Board #118

Poster
Abstract 11149: Association between body mass index and overall survival in veterans receiving immune checkpoint inhibitors
Session: Quality Care/Health Services Research
Presenter: Abhishek Bhattacharya, MD
Time: 1:30–4:30 PM
Location: Hall A, Poster Board #488

Sunday, June 1

Poster
Abstract 5519: Impact of pre-treatment counseling on uptake of hormone replacement therapy in patients undergoing chemoradiation for cervical cancer
Session: Gynecologic Cancer
Presenter: Keizra Mecklai, MD, MBA
Time: 9:00 AM–12:00 PM
Location: Hall A, Poster Board #299

Poster
Abstract 1564: Comparison of artificial intelligence to expert physician assessments of real-world oncology cases
Session: Care Delivery/Models of Care
Presenter: Olivia Main, MD
Time: 9:00 AM–12:00 PM
Location: Hall A, Poster Board #330

Education Session
Artificial Intelligence and the Future of Brain Tumor Surgery: Transforming Diagnosis and Treatment
Session: State of the Art in Utilizing Artificial Intelligence in Neuro-Oncology
Presenter: Daniel A. Orringer, MD
Time: 11:30 AM–11:45 PM
Location: E350

Rapid Oral Abstract Session
Abstract 2517: Role of autoimmune reactivity in neurotoxicities (N-Tox) in melanoma patients treated with immune-checkpoint inhibitors (ICI)
Session: Developmental Therapeutics—Immunotherapy
Presenter: Agrima Dutt, MS
Time: 11:57 AM–12:03 PM
Location: S406

Monday, June 2

Poster
Abstract 549: Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts
Session: Breast Cancer—Local/Regional/Adjuvant
Presenter: Jan Witowski, MD, PhD
Time: 9:00 AM–12:00 PM
Location: Hall A, Poster Board #142

Poster
Abstract 5067: Phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Presenter: David R. Wise, MD, PhD
Time: 9:00 AM–12:00 PM
Location: Hall A, Poster Board #266

Poster
Abstract 5053: Real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) and AR T878A alterations treated with enzalutamide
Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Presenter: Matthew Siskin, MD
Time: 9:00 AM–12:00 PM
Location: Hall A, Poster Board #252

Poster
Abstract 1079: Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study
Session: Breast Cancer—Metastatic
Presenter: Nancy Chan, MD
Time: 9:00 AM–12:00 PM
Location: Hall A, Poster Board #58

Poster
Abstract 1112: Immunotherapy vs. chemotherapy run-in followed by pembrolizumab plus nab-paclitaxel in metastatic triple negative breast cancer (mTNBC): Results from a phase II study
Session: Breast Cancer—Metastatic
Presenter: Alessandro Leal, MD, PhD
Time: 9:00 AM–12:00 PM
Location: Hall A, Poster Board #91

Poster
Abstract TPS4629: The uTRACT registry: A single-arm, multicenter, prospective, and retrospective registry study to evaluate the real-world use of UGN-101 in participants with upper tract urothelial carcinoma (UTUC) in the United States
Session: Genitourinary Cancer—Kidney and Bladder
Presenter: Katie S. Murray, DO
Time: 9:00 AM–12:00 PM
Location: Hall A, Poster Board #420a

Rapid Oral Abstract Session
Abstract 9510: A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma
Session: Melanoma/Skin Cancers
Presenter: Janice Mehnert, MD
Time: 9:51–9:57AM
Location: E451

Poster
Abstract 3040: EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH)
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Presenter: Salman Rafi Punekar, MD
Time: 1:30–4:30 PM
Location: Hall A, Poster Board #355

Oral Abstract Session
Abstract 10507: Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study
Session: Prevention, Risk Reduction, and Genetics
Presenter: Lucas A Mavromatis, BSc
Time: 1:42 PM–1:54 PM
Location: S100a, Live Stream